{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:41Z","timestamp":1780561421584,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109256","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:27:25Z","timestamp":1663676845000},"page":"109256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Tapering biologics in axial spondyloarthritis: A systematic literature review"],"prefix":"10.1016","volume":"112","author":[{"given":"Miladi","family":"Saoussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhlouf","family":"Yasmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacef","family":"Lilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazaa","family":"Alia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bousaa","family":"Hiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Abdelghani","family":"Kawther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laatar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.109256_b0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.109256_b0015","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/annrheumdis-2015-208730","article-title":"Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis","volume":"75","author":"Sepriano","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.109256_b0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.109256_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010455.pub3","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","author":"Verhoef","year":"2019","journal-title":"Cochrane Musculoskeletal Group, \u00e9diteur. Cochrane Database Syst Rev [Internet]."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2018-213547","article-title":"Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key","volume":"78","author":"den Broeder","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.109256_b0035","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/art.40546","article-title":"An economic evaluation of stopping versus continuing tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients with disease remission or low disease activity: results from a pragmatic open-label trial","volume":"70","author":"Tran-Duy","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109256_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.intimp.2022.109256_b0045","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109256_b0050","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.109256_b0055","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.141313","article-title":"Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis","volume":"42","author":"Dougados","year":"2015","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109256_b0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.rdc.2012.08.001","article-title":"How Important is Early Therapy in Axial Spondyloarthritis?","volume":"38","author":"Sieper","year":"2012","journal-title":"Rheum. Dis. Clin. N Am."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13063-015-0828-5","article-title":"Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial","volume":"16","author":"Pontes","year":"2015","journal-title":"Trials."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","article-title":"Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study","volume":"21","author":"REMINEA study Group","year":"2019","journal-title":"Arthritis Res Ther."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2022.109256_b0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31138\/mjr.30.1.63","article-title":"The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice","volume":"30","author":"Kravvariti","year":"2019","journal-title":"Mediterr J. Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109256_b0080","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.intimp.2022.109256_b0085","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.intimp.2022.109256_b0090","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0019-5413.30519","article-title":"The hierarchy of evidence: Levels and grades of recommendation","volume":"41","author":"Petrisor","year":"2007","journal-title":"Indian J. Orthop."},{"issue":"6","key":"10.1016\/j.intimp.2022.109256_b0105","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","article-title":"Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission","volume":"37","author":"Chen","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109256_b0110","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","author":"De Stefano","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109256_b0115","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109256_b0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00296-016-3428-0","article-title":"Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy","volume":"36","author":"Almirall","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2022.109256_b0125","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109256_b0130","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","article-title":"Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity","volume":"42","author":"Plasencia","year":"2015","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109256_b0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109256_b0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25 mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109256_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/289845","article-title":"Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study","author":"M\u00f6rck","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study","volume":"75","author":"Z\u00e1vada","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109256_b0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5114\/aoms.2018.76141","article-title":"Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China","volume":"15","author":"Li","year":"2019","journal-title":"Arch Med Sci."},{"issue":"7","key":"10.1016\/j.intimp.2022.109256_b0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.intimp.2022.109256_b0170","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"1","author":"Cantini","year":"2013","journal-title":"Biol. Targets Ther."},{"issue":"10","key":"10.1016\/j.intimp.2022.109256_b0175","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.autrev.2011.04.015","article-title":"Anti-TNF\u03b1 discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?","volume":"10","author":"Chimenti","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"10142","key":"10.1016\/j.intimp.2022.109256_b0180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"The Lancet."},{"issue":"2","key":"10.1016\/j.intimp.2022.109256_b0185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/039463200902200221","article-title":"Imaging Progression despite Clinical Remission in Early Rheumatoid Arthritis Patients after Etanercept Interruption","volume":"22","author":"Lagan\u00e0","year":"2009","journal-title":"Int.. J. Immunopathol. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109256_b0190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2022.109256_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028517","volume":"9","author":"Uhrenholt","year":"2019","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.intimp.2022.109256_b0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3899\/jrheum.200586","article-title":"The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis","volume":"49","author":"Alonso","year":"2022","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109256_b0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4103\/jfmpc.jfmpc_145_17","article-title":"Biopsychosocial model of illnesses in primary care: a hermeneutic literature review","volume":"7","author":"Kusnanto","year":"2018","journal-title":"J. Fam. Med. Prim. Care."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:20Z","timestamp":1761587180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":41,"alternative-id":["S1567576922007408"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109256","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapering biologics in axial spondyloarthritis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109256"}}